Trials / Terminated
TerminatedNCT03947762
Lanreotide 120mg Effectiveness in Subjects With Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice.
Lanreotide 120 mg Effectiveness in Subjects With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumours (PanNET) in Routine Clinical Practice
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 54 (actual)
- Sponsor
- Ipsen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the protocol is to estimate the progression-free survival (PFS) rate in subjects diagnosed with PanNET, according to investigator assessment, at 24 months after treatment initiation with lanreotide 120 mg every 28 days.
Conditions
Timeline
- Start date
- 2019-07-03
- Primary completion
- 2021-04-30
- Completion
- 2021-04-30
- First posted
- 2019-05-13
- Last updated
- 2021-06-14
Locations
46 sites across 2 countries: Portugal, Spain
Source: ClinicalTrials.gov record NCT03947762. Inclusion in this directory is not an endorsement.